FDA approves Myoview for use with stress agents:
This article was originally published in Clinica
Executive Summary
Amersham Health has received US FDA approval for the additional use of its Myoview radiopharmaceutical with pharmacological stress agents, which are used in the diagnosis of coronary artery diseases in patients unable to exercise physically. The product was introduced in the US in 1996 where it has captured over 35% of the technetium cardiac market says the UK-based firm.